首页> 外文期刊>Vaccine >Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.
【24h】

Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.

机译:基于与木瓜花叶病毒(PapMV)疫苗平台融合的M2e肽的通用A型流感疫苗的开发。

获取原文
获取原文并翻译 | 示例
       

摘要

With the emergence of highly virulent influenza viruses and the consequent risk of pandemics, new approaches to designing universal influenza vaccines are urgently needed. In this report, we demonstrate the potential of using a papaya mosaic virus (PapMV) platform carrying the universal M2e influenza epitope (PapMV-CP-M2e) as a candidate flu vaccine. We show that PapMV-CP-M2e virus-like particles (VLPs) can induce production in mice of anti-M2e antibodies that can recognize influenza-infected cells. PapMV-CP-M2e discs made of 20 coat protein (CP) subunits were shown to be poorly immunogenic compared to PapMV-CP-M2e VLPs composed of several hundred CP subunits. We also show that addition of either alum or PapMV-CP VLPs as adjuvant dramatically increased the immunogenicity of PapMV-CP-M2e-containing vaccine, and led to 100% protection against a challenge of 4LD(50) with the WSN/33 strain. These results show, for the first time, the potential of a recombinant plant virus protein to serve as both peptide delivery system and adjuvant in the crucial field of influenza vaccine development.
机译:随着高毒性流感病毒的出现以及随之而来的大流行风险,迫切需要设计通用流感疫苗的新方法。在本报告中,我们证明了使用带有通用M2e流感抗原决定簇(PapMV-CP-M2e)的木瓜花叶病毒(PapMV)平台作为候选流感疫苗的潜力。我们显示,PapMV-CP-M2e病毒样颗粒(VLPs)可以诱导抗M2e抗体在小鼠中产生,该抗体可以识别感染流感的细胞。与由数百个CP亚基组成的PapMV-CP-M2e VLP相比,由20个外壳蛋白(CP)亚基制成的PapMV-CP-M2e光盘显示出较弱的免疫原性。我们还显示,添加明矾或PapMV-CP VLPs作为佐剂可显着增加含PapMV-CP-M2e的疫苗的免疫原性,并导致100%保护免受WSN / 33菌株对4LD(50)的攻击。这些结果首次显示了重组植物病毒蛋白在流感疫苗开发的关键领域中既可作为肽传递系统又可作为佐剂的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号